A phase III study for evaluating the RESOLVE steroid releasing implant for the treatment of recurrent sinus obstruction post-surgery in patients with chronic sinusitis, in the office setting

Trial Profile

A phase III study for evaluating the RESOLVE steroid releasing implant for the treatment of recurrent sinus obstruction post-surgery in patients with chronic sinusitis, in the office setting

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Mometasone (Primary)
  • Indications Sinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms RESOLVE II
  • Sponsors Intersect ENT
  • Most Recent Events

    • 22 Jan 2018 Results were published in the International Forum of Allergy & Rhinology according to an Intersect ENT media release.
    • 22 Jan 2018 Results presented in an Intersect ENT Media Release.
    • 11 Dec 2017 According to an Intersect ENT media release,U.S. Food and Drug Administration (FDA) has approved the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top